Loading...
Resmetirom (MGL-3196) is an oral, liver-directed, selective thyroid hormone receptor beta agonist. It regulates metabolic pathways in the liver that are impaired in nonalcoholic fatty liver disease.
In an industry-funded, 36-week, phase II trial conducted across 25 U.S. sites, researchers assessed the safety and efficacy of resmetirom in patients with biopsy-proven nonalcoholic steatohepatitis (NASH), fibrosis stage 1 to 3, and at least 10% hepatic fat fraction (assessed by MRI-proton density fat fraction). Patients were randomized in a 2:1 ratio to receive resmetirom 80 mg (n=84) or placebo (n=41) orally once daily. Resmetirom dose was adjusted (range, 40–100 mg) at week 4 based on serum drug concentration measured at week 2.
The relative re…